Pipes Feed Preview: ClinicalTrials.gov: COVID-19 | Last update posted in the last 14 days

1. Clinical Validation of the Aptitude Medical Systems Metrix COVID-19 Test

   Fri, 20 Dec 2024 05:00:00 -0000

   Conditions: COVID-19; COVID
   Interventions: Diagnostic Test: Aptitude Medical Systems Metrix COVID Test
   Sponsors: Aptitude Medical Systems; Biomedical Advanced Research and Development Authority
   Recruiting

2. A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults

   Thu, 19 Dec 2024 05:00:00 -0000

   Conditions: COVID-19
   Interventions: Biological: CVXGA (CVXGA50); Biological: COMIRNATY®
   Sponsors: CyanVac LLC; Biomedical Advanced Research and Development Authority
   Recruiting

3. Secondary Databased Post-marketing Surveillance Study of BNT162b2

   Thu, 19 Dec 2024 05:00:00 -0000

   Conditions: COVID-19; SARS-CoV-2
   Interventions: Biological: Tozinameran (BNT162b2); Biological: Tozinameran (BNT162b2) / Riltozinameran (BNT162b2 OMI BA.1); Biological: Tozinameran (BNT162b2) / Famtozinameran (BNT162b2 OMI BA.4-5)
   Sponsors: Pfizer
   Not yet recruiting

4. Humanity Neurotech Device Clinical Trial in Adults with Long COVID Cognitive Dysfunction

   Wed, 18 Dec 2024 05:00:00 -0000

   Conditions: Post-Acute COVID-19 Syndrome; Cognitive Dysfunction
   Interventions: Device: Pascal device; Device: Sham Device
   Sponsors: Icahn School of Medicine at Mount Sinai; Humanity Neurotech Inc.
   Recruiting

5. Bern, Get Ready (BEready) Cohort Study for Pandemic Preparedness

   Wed, 18 Dec 2024 05:00:00 -0000

   Conditions: Pandemic, COVID-19; Infections; Zoonoses; Epidemic Disease; Respiratory Tract Infections
   Sponsors: University of Bern; Stiftung Vinetum
   Recruiting

6. Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use

   Mon, 16 Dec 2024 05:00:00 -0000

   Conditions: COVID-19; Influenza a; Influenza B
   Interventions: Diagnostic Test: COVID/Flu Detect™ Rapid Self-Test
   Sponsors: InBios International, Inc.
   Not yet recruiting

7. Saliva PCR in Pregnant Women with COVID-19

   Mon, 16 Dec 2024 05:00:00 -0000

   Conditions: Coronavirus Disease 2019 (COVID-19) Pneumonia
   Interventions: Drug: Nirmatrelvir/Ritonavir (Paxlovid)
   Sponsors: National Cheng-Kung University Hospital
   Completed

8. Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV

   Thu, 12 Dec 2024 05:00:00 -0000

   Conditions: HIV Infections
   Sponsors: University of Toronto
   Completed

9. STUDY to EVALUATE the ROLE of T CELL-DYSFUNCTION in SYMPTOMS ASSOCIATED with LONG COVID, LYME DISEASE and MYALGIC ENCEPHALOMYELITIS/CHRONIC FATIGUE SYNDROME USING the VIRAXIMMUNE FLUOROSPOT T CELL ASSAY

   Thu, 12 Dec 2024 05:00:00 -0000

   Conditions: Symptoms Associated with a Diagnosis of Long COVID, PTLDS or ME/CFS
   Sponsors: ViraxBio Labs
   Not yet recruiting

10. Noninvasive Neuromodulation in the Management of Post-COVID Musculoskeletal Pain

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: COVID-19; Musculoskeletal Pain
    Interventions: Other: Neuromodulation group; Other: Neuromodulation sham group
    Sponsors: University of Alcala
    Recruiting

11. Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated; Biological: Not vaccinated with 2024-2025 formulated COVID-19 vaccine
    Sponsors: Pfizer; CVS Caremark
    Active, not recruiting

12. A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: SARS-CoV-2 Infections
    Interventions: Drug: Treatment B; Drug: Treatment A
    Sponsors: Pfizer
    Recruiting

13. A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: Coronavirus Disease (COVID-19)
    Interventions: Drug: Molnupiravir; Drug: Placebo
    Sponsors: Merck Sharp & Dohme LLC
    Recruiting

14. Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: Pneumonia, Community-Acquired; COVID-19 Pneumonia; Cardiovascular Diseases
    Interventions: Other: Blood samples and Oropharyngeal swab; Other: Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
    Sponsors: Hellenic Institute for the Study of Sepsis
    Recruiting

15. Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: PASC Post Acute Sequelae of COVID-19
    Sponsors: National Institute of Neurological Disorders and Stroke (NINDS)
    Not yet recruiting

16. Covid-19 Long Immunité IMagerie (CLIIM)

    Thu, 12 Dec 2024 05:00:00 -0000

    Conditions: COVID Long-Haul
    Interventions: Procedure: Brain MRI; Biological: Specific blood samples
    Sponsors: Centre Hospitalier Universitaire de Nice
    Not yet recruiting

17. Antiviral Clinical Trial for Long Covid-19

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: Long Covid
    Interventions: Drug: tenofovir disoproxil/emtricitabine; Drug: Selzentry; Drug: Placebo
    Sponsors: Icahn School of Medicine at Mount Sinai; Yale University; PolyBio Research Foundation
    Recruiting

18. Cognitive Muscular Therapy for Patients with Long-COVID and Breathing Pattern Disorder

    Tue, 17 Dec 2024 05:00:00 -0000

    Conditions: Long COVID; Respiratory Disease
    Interventions: Behavioral: Cognitive Muscular Therapy; Behavioral: Breathing visualisation
    Sponsors: University of Salford
    Recruiting

19. Lot Consistency Study of COVID-19 and Influenza Combination Vaccine

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: COVID-19; Influenza
    Interventions: Biological: coformulated CIC Vaccine; Biological: Fluzone HD trivalent
    Sponsors: Novavax
    Not yet recruiting

20. Electronic Health Record Strategies to Promote Diverse Participation in Research AIM 2

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: Patient Participation
    Interventions: Other: Traditional Letter; Other: Direct to Patient Message; Other: Optimized Letter; Other: Direct to Patient Message - Optimized
    Sponsors: Yale University; Food and Drug Administration (FDA)
    Recruiting

21. Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: MPV/S-2P
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Active, not recruiting

22. A Strain Change Study for SARS-CoV-2 rS Vaccines

    Tue, 17 Dec 2024 05:00:00 -0000

    Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 Infection
    Interventions: Biological: NVX-CoV2705 Vaccine
    Sponsors: Novavax
    Active, not recruiting

23. RECOVER-AUTONOMIC Platform Protocol

    Mon, 16 Dec 2024 05:00:00 -0000

    Conditions: Long COVID; Long Covid19; Long Covid-19
    Interventions: Drug: IVIG + Coordinated Care; Drug: IVIG Placebo + Coordinated Care; Drug: Ivabradine + Coordinated Care; Drug: Ivabradine Placebo + Coordinated Care; Drug: IVIG + Usual Care; Drug: IVIG Placebo + Usual Care; Drug: Ivabradine + Usual Care; Drug: Ivabradine Placebo + Usual Care
    Sponsors: Kanecia Obie Zimmerman
    Recruiting

24. Severe Group a Streptococcus Infections in Paris, France, 2018-2023

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: Invasive Group a Beta-Haemolytic Streptococcal Disease
    Interventions: Other: Collection of data from the patient's medical file
    Sponsors: Assistance Publique - Hôpitaux de Paris
    Completed

25. Immunogenicity and Safety Study of Self-amplifying MRNA COVID-19 Vaccine Administered with Influenza Vaccines in Adults

    Mon, 16 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: ARCT-2303; Biological: Influenza vaccine; Biological: Influenza vaccine, adjuvanted; Other: Placebo
    Sponsors: Arcturus Therapeutics, Inc.; Seqirus; Novotech (Australia) Pty Limited
    Completed

26. A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: Influenza; COVID-19
    Interventions: Biological: Influenza and COVID-19 Combination A; Biological: Licensed influenza vaccine; Biological: COVID-19 Vaccine; Biological: Influenza and COVID-19 Combination B; Biological: Placebo; Biological: Investigational influenza vaccine
    Sponsors: BioNTech SE; Pfizer
    Completed

27. Left Atrial Function of COVID-19-recovered Patients During the Surge of Omicron Variants

    Tue, 17 Dec 2024 05:00:00 -0000

    Conditions: COVID-19 Pandemic
    Interventions: Other: two-dimensional speckle tracking echocardiography
    Sponsors: Haiyan Wang
    Completed

28. Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: Influenza; COVID-19; SARS-COV-2 Infection; Other Respiratory Viruses; Perinatal Morbidity; Infant Morbidity
    Interventions: Other: Exposures
    Sponsors: Boston University; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Lata Medical Research Foundation, Nagpur
    Recruiting

29. COVID-19 Personal Protective Equipment for Vaccinated Health Workers and Convalescents

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Other: Personal Protective Equipment
    Sponsors: University Medical Centre Ljubljana
    Withdrawn

30. Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: SARS-CoV-2
    Interventions: Biological: SPIKEVAX
    Sponsors: ModernaTX, Inc.; Aetion, Inc.
    Completed

31. Psychosomatic, Physical Activity or Both for Post-covid19 Syndrom

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: Post-COVID-19 Syndrome
    Interventions: Behavioral: Exercise Therapy; Behavioral: Psychotherapy
    Sponsors: Hannover Medical School; Health Insurance Audi BKK; occupational health service Volkswagen AG; Helmholtz Centre for Infection Research
    Recruiting

32. COVID-19 Vaccination Hesitancy in Adults With Sickle Cell Disease

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: Sickle Cell Disease; COVID-19 Vaccine; Vaccine Hesitancy
    Interventions: Behavioral: SCD-specific COVID-19 vaccination information (SCVI) video
    Sponsors: Duke University; American Society of Hematology
    Completed

33. Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: NVX-CoV2373 (5μg); Biological: NVX-CoV2601 (5μg); Biological: NVX-CoV2601(5μg); Biological: NVX-CoV2601 (35μg); Biological: NVX-CoV2601(35μg); Biological: NVX-CoV2601(50μg); Biological: Bivalent BA.4/5
    Sponsors: Novavax
    Completed

34. NC Testing in LC & POTS

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: Postural Orthostatic Tachycardia Syndrome; Post Acute Sequelae of SARS CoV 2 Infection
    Interventions: Other: IV normal saline (999 mL infusion); Other: IV normal saline (50 mL infusion)
    Sponsors: University of Calgary
    Recruiting

35. A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: Healthy Participants
    Interventions: Biological: Combination [RSVpreF+BNTb162b2]; Biological: Bivalent BNT162b2 (original/Omi BA.4/BA.5); Biological: RSVpreF; Biological: QIV; Biological: Normal Saline Placebo
    Sponsors: Pfizer
    Completed

36. Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: SARS-CoV-2; COVID-19; Post-Acute COVID-19 Syndrome
    Interventions: Biological: Pfizer-BioNTech COVID-19 mRNA vaccine
    Sponsors: Pfizer
    Recruiting

37. Lung Function in Post-COVID-19 Nursing Home Residents

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: Post-COVID-19 Syndrome
    Interventions: Other: Previous exposure to SARS-CoV-2
    Sponsors: University of Vic - Central University of Catalonia; Catalan Board of Physiotherapists
    Completed

38. Digital Mental Health Care for COVID-19 High-Risk Populations - Phase 2

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: Stigma, Social; Help-Seeking Behavior
    Interventions: Other: Adjusted Content Intervention; Other: Non-Adjusted Intervention Video
    Sponsors: Research Foundation for Mental Hygiene, Inc.; Columbia University
    Completed

39. Long COVID and Its Associations With Health Outcomes in Older Adults

    Thu, 12 Dec 2024 05:00:00 -0000

    Conditions: Long COVID; COVID-19 Pandemic; Elderly Infection; Vaccine Reaction; Lifestyle Factors; Reinfection
    Interventions: Other: no interventions
    Sponsors: Peking University; National Natural Science Foundation of China
    Active, not recruiting

40. Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial

    Thu, 12 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: abatacept infusion; Drug: Placebo group
    Sponsors: University of Minnesota
    Recruiting

41. Mucosal Immunity: Influence on Infectious Viral Load: a Prospective Observational Study

    Mon, 16 Dec 2024 05:00:00 -0000

    Conditions: SARS-CoV-2 Infection; Influenza Viral Infections; Virus Shedding; Mucosal Immunity; RSV Infection
    Interventions: Other: No intervention
    Sponsors: University Hospital, Geneva; University of Geneva, Switzerland; ModernaTX, Inc.
    Active, not recruiting

42. Cluster-Randomized Trial of Air Filtration and Ventilation to Reduce Covid19 Spread in Homes

    Mon, 16 Dec 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Device: Filtration Fan; Behavioral: Safe-home pamphlet; Behavioral: Mid-week phone call
    Sponsors: Stanford University; National Institute of Allergy and Infectious Diseases (NIAID)
    Enrolling by invitation

43. Study of Obeldesivir in Nonhospitalized Participants With COVID-19

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Obeldesivir; Drug: Obeldesivir Placebo
    Sponsors: Gilead Sciences
    Completed

44. Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: Long COVID; Post-COVID Syndrome; Post COVID-19 Condition
    Interventions: Biological: RegeneCyte; Biological: Placebo
    Sponsors: StemCyte International, Ltd.; StemCyte, Inc.
    Active, not recruiting

45. Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients with Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: SARS CoV-2 Post-Acute Sequelae
    Interventions: Drug: DPA-714 PET/MRI
    Sponsors: University of Alabama at Birmingham
    Recruiting

46. Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

    Thu, 12 Dec 2024 05:00:00 -0000

    Conditions: COVID-19, SARS-CoV-2
    Interventions: Biological: AZD5156 (Parent study Sentinel Safety Cohort); Biological: Placebo (Parent study Sentinel Safety Cohort); Biological: EVUSHELD™ (Parent study Main Cohort); Biological: AZD3152 (Parent study Main Cohort); Biological: Placebo (Parent study Main Cohort); Biological: AZD3152 (Sub-study); Biological: AZD7442 - EVUSHELD™ (Sub-study); Biological: AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
    Sponsors: AstraZeneca
    Active, not recruiting

47. Post-COVID-19 Chronic Fatigue Syndrome

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: Post-COVID-19 Syndrome; Post-COVID Syndrome
    Interventions: Drug: Synthetic Vitamin B1
    Sponsors: ClinAmygate; As-Salam Center, Maadi, Cairo, Egypt
    Active, not recruiting

48. Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: Viral Lung Infection and Acute Respiratory Failure
    Interventions: Drug: Tozorakimab; Drug: Placebo
    Sponsors: AstraZeneca
    Recruiting

49. Dietary Modulation of Gut Microbiota in Overweight/Obese Adolescents and COVID-19 Infection

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: Health Behavior; Child Development; Adolescent Obesity
    Interventions: Dietary Supplement: Probiotics; Behavioral: Counselling on healthy eating, physical activity, and psychosocial stimulation; Dietary Supplement: Placebo probiotics
    Sponsors: Indonesia University; Gadjah Mada University; Universitas Airlangga; University of Melbourne; The Indonesia Endowment Funds for Education, Ministry of Finance Indonesia
    Recruiting

50. Nitrite Supplementation in Long COVID Patients

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: Long COVID; Cardiorespiratory Fitness
    Interventions: Dietary Supplement: 210 ml per day of Beet-It nitrate beverage (James White Drinks Ltd., Ipswich, UK)
    Sponsors: VA Office of Research and Development; University of Pittsburgh
    Recruiting

51. Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Paxlovid; Drug: Other; Other: Other
    Sponsors: Unity Health Toronto; Health Canada; Canadian Institutes of Health Research (CIHR)
    Recruiting

52. Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Shionogi Protease Inhibitor (S-217622); Drug: placebo
    Sponsors: University of Minnesota; National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

53. Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Obeldesivir; Drug: Obeldesivir Placebo
    Sponsors: Gilead Sciences
    Terminated

54. Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST): Prospective COVID-19 Natural History Study

    Mon, 16 Dec 2024 05:00:00 -0000

    Conditions: Heart Disease
    Sponsors: National Human Genome Research Institute (NHGRI)
    Completed

55. Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to < 12 Years

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period); Other: Placebo
    Sponsors: Novavax
    Active, not recruiting

56. Pathophysiology of Gas Exchange and Time Course Changes in Spontaneously Breathing Patients With Acute Respiratory Failure Due to COVID-19. A Multicenter Prospective Study.

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: Respiratory Insufficiency
    Interventions: Other: Pathophysiology of gas exchange
    Sponsors: CHU de Reims
    Completed

57. A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults

    Tue, 17 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: Prime-2-CoV_Beta
    Sponsors: University Hospital Tuebingen; FGK Clinical Research GmbH; VisMederi srl; Staburo GmbH; Viedoc Technologies AB
    Suspended

58. Olfactory Training As a Treatment for Olfactory Dysfunction Post COVID-19

    Tue, 17 Dec 2024 05:00:00 -0000

    Conditions: Hyposmia; COVID-19; Parosmia; Anosmia; SARS-CoV-2 Infection
    Interventions: Other: Smell training
    Sponsors: Université du Québec à Trois-Rivières
    Recruiting

59. COVID-19 Experiences in the SELF Cohort

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute of Environmental Health Sciences (NIEHS)
    Enrolling by invitation

60. Exercise in Child Health

    Mon, 16 Dec 2024 05:00:00 -0000

    Conditions: Cystic Fibrosis; Sickle Cell Disease; SARS CoV 2 Infection
    Interventions: Other: Exercise
    Sponsors: University of California, Irvine; Children's Hospital of Orange County; Children's Hospital Los Angeles; Ann & Robert H Lurie Children's Hospital of Chicago
    Recruiting

61. Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation

    Tue, 24 Dec 2024 05:00:00 -0000

    Conditions: Severe COVID-19
    Sponsors: Assistance Publique - Hôpitaux de Paris
    Recruiting

62. Evaluation of Full Versus Fractional Doses of COVID-19 Vaccines Given as a Booster in Adults in Australia - Mongolia, Indonesia, Australia Coronavirus (MIACoV).

    Mon, 16 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Biological: Tozinameran - Standard dose; Biological: Tozinameran - fractional dose; Biological: Elasomeran - standard dose; Biological: Elasomeran - fractional dose
    Sponsors: Murdoch Childrens Research Institute; Coalition for Epidemic Preparedness Innovations; The Peter Doherty Institute for Infection and Immunity
    Terminated

63. The SINCERE Intervention to Address COVID-19 Health Disparities

    Thu, 12 Dec 2024 05:00:00 -0000

    Conditions: COVID-19; Vulnerable Populations; Social Determinants of Health
    Interventions: Behavioral: SINCERE; Behavioral: Scheduled Follow-Up; Other: Standard of Care
    Sponsors: Andrea Wallace; National Institute of Nursing Research (NINR)
    Recruiting

64. Digital Nutrition Intervention for Older Adults

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: Nutrition Poor; Physical Inactivity; Social Isolation
    Interventions: Behavioral: Technology intervention; Behavioral: Digital Nutrition Intervention
    Sponsors: The University of Texas at San Antonio; National Institute of Nursing Research (NINR); Older Adult Technology Services; City of San Antonio Department of Human Services; Agile Analytics, LLC
    Active, not recruiting

65. Correction of Metabolic Disorders and Its Effect on Respiratory Function of Lungs in Patients With Severe COVID-19

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Interventions: Drug: Reamberin; Drug: Ringer's solution
    Sponsors: POLYSAN Scientific & Technological Pharmaceutical Company
    Completed

66. Extension Study in a Cohort of Adult Patients With COVID-19 Infection

    Thu, 12 Dec 2024 05:00:00 -0000

    Conditions: COVID-19 Infection
    Interventions: Drug: Plitidepsin 1.5 mg / day; Drug: Plitidepsin 2.0 mg / day; Drug: Plitidepsin 2.5 mg / day
    Sponsors: PharmaMar; Apices Soluciones S.L.
    Completed

67. Mobile Health and COVID-19

    Tue, 17 Dec 2024 05:00:00 -0000

    Conditions: Anxiety Depression
    Interventions: Other: EASE app; Other: INSIGHT (Control) App
    Sponsors: University of Houston; University of Oklahoma; Oklahoma State University
    Completed

68. A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: COVID-19; SARS-CoV-2 Infection; Corona Virus Infection
    Interventions: Biological: ARCT-165; Biological: ARCT-154; Biological: ARCT-021
    Sponsors: Arcturus Therapeutics, Inc.
    Completed

69. Cerebral Autoregulation and COVID-19

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: COVID-19 Acute Respiratory Distress Syndrome; COVID-19 Pneumonia
    Interventions: Other: NIRS (Near-Infrared Spectroscopy)
    Sponsors: University of Athens
    Terminated

70. MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: Asthma; COPD; Covid19; Long COVID
    Sponsors: Sheffield Teaching Hospitals NHS Foundation Trust; University of Sheffield
    Suspended

71. Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: Alcoholic Liver Disease; COVID 19 Pneumonia
    Interventions: Dietary Supplement: β-hydroxy β-methyl butyrate (HMB) enriched amino acid; Dietary Supplement: Balanced amino acid
    Sponsors: The Cleveland Clinic
    Recruiting

72. A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute on Aging (NIA)
    Recruiting

73. Rapid Detection of COVID-19 by Portable and Connected Biosensor : Biological Proof of Concept

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: SARS-CoV Infection; Covid19
    Interventions: Diagnostic Test: COVID-19 RT-PCR; Diagnostic Test: Biosensor
    Sponsors: University Hospital, Lille
    Completed

74. Expressive Writing for the Management of Stress in Cancer Survivors

    Wed, 18 Dec 2024 05:00:00 -0000

    Conditions: Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm
    Interventions: Behavioral: Behavioral Intervention; Behavioral: Behavioral Intervention; Behavioral: Behavioral Intervention; Behavioral: Behavioral Intervention; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
    Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
    Recruiting

75. Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19

    Mon, 16 Dec 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Drug: Silmitasertib; Drug: SOC
    Sponsors: Senhwa Biosciences, Inc.
    Completed

76. WEAICOR: Wearables to Investigate the Long Term Cardiovascular and Behavioral Impacts of COVID-19

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: Covid19; Cardiovascular Complication; Behavioral Changes
    Sponsors: Tulane University; Biostrap
    Active, not recruiting

77. COVID-19 Survivorship Registry

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: Covid19
    Interventions: Other: Questionnaires
    Sponsors: NYU Langone Health
    Recruiting

78. TARGet Kids! COVID-19 Study of Children and Families

    Tue, 17 Dec 2024 05:00:00 -0000

    Conditions: Coronavirus; COVID-19; Virus; Family and Household; Infection Viral
    Sponsors: The Hospital for Sick Children; Unity Health Toronto
    Completed

79. A Longitudinal Study of COVID-19 Sequelae and Immunity

    Thu, 12 Dec 2024 05:00:00 -0000

    Conditions: COVID-19
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Active, not recruiting

80. NCI COVID-19 in Cancer Patients, NCCAPS Study

    Tue, 17 Dec 2024 05:00:00 -0000

    Conditions: COVID-19 Infection; Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm
    Interventions: Procedure: Biospecimen Collection; Other: Data Collection; Other: Quality-of-Life Assessment; Other: Questionnaire Administration
    Sponsors: National Cancer Institute (NCI)
    Active, not recruiting

81. Rapid Detection of COVID-19 by Portable and Connected Biosensor

    Tue, 17 Dec 2024 05:00:00 -0000

    Conditions: Sars-CoV2
    Interventions: Diagnostic Test: COVID-19 RT-PCR; Diagnostic Test: Biosensor
    Sponsors: University Hospital, Lille
    Completed

82. COVID-19 Recovered Volunteer Research Participant Pool Registry

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: Recovered From COVID-19
    Sponsors: University of California, Los Angeles
    Active, not recruiting

83. Pro-thrombotic Status in Patients with SARS-Cov-2 Infection

    Thu, 12 Dec 2024 05:00:00 -0000

    Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
    Interventions: Other: SARS-Cov-2 infection
    Sponsors: University Hospital of Ferrara
    Completed

84. Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

    Thu, 19 Dec 2024 05:00:00 -0000

    Conditions: Sickle Cell Disease (SCD)
    Interventions: Drug: Crizanlizumab
    Sponsors: Novartis Pharmaceuticals
    Active, not recruiting

85. High Resolution Micro OCT Imaging

    Fri, 13 Dec 2024 05:00:00 -0000

    Conditions: Cystic Fibrosis; COPD; PCD - Primary Ciliary Dyskinesia; Covid19; Sinusitis
    Sponsors: University of Alabama at Birmingham; Massachusetts General Hospital
    Recruiting

86. Viral Infections in Healthy and Immunocompromised Hosts

    Fri, 20 Dec 2024 05:00:00 -0000

    Conditions: Anogenital Herpes; COVID-19; Herpes Labialis
    Sponsors: National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting